Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Description

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Conditions

Chronic Low-back Pain, Vertebrogenic Pain Syndrome

Study Overview

Study Details

Study overview

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Condition
Chronic Low-back Pain
Intervention / Treatment

-

Contacts and Locations

Larkspur

MarinHealth Spine Institute, Larkspur, California, United States, 94939

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
  • * Signed a valid, IRB/EC-approved informed consent form.
  • * Meets any contraindications per locally applicable Instructions for Use (IFU).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Boston Scientific Corporation,

Natalie Bloom Lyons, M.A., STUDY_DIRECTOR, Boston Scientific Corporation

Study Record Dates

2034-07